RNANasdaq

Atrium Therapeutics Inc.

Healthcare·Rare Disease·Phase 3·San Diego, CA, United States
Rare DiseaseCardiovascular

Atrium Therapeutics Inc. (RNA): ~26 mo cash runway. Updated within the last hour.

8.5/10

BioSniper Score

2-factor signal · derived from public data

Cash Runway7.3

26.3 months

Financial Health9.6

D/E 0.25 · 0% dilution

Pipeline MaturityN/A

N/A

Pipeline BreadthN/A

N/A

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for Atrium Therapeutics Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$218.1M

Cash

$268.3M

Quarterly Burn

$31.1M

Runway

26.3 mo

Revenue

$19.6M

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Aug 2028
Today~29 mo out
Catalyst within runway

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

156

Total value held

$179.6M

HolderSharesValue
vanguard capital management llc1,253,738$16.8M
blackrock, inc.1,205,291$16.1M
susquehanna international group, llp1,030,143$13.8M
ra capital management, l.p.864,102$11.6M
pentwater capital management lp602,649$8.1M
goldman sachs group inc349,950$4.7M
farallon capital management llc349,360$4.7M
vanguard portfolio management llc344,369$4.6M
geode capital management, llc319,831$4.3M
683 capital management, llc300,000$4.0M

Showing top 10 of 156 institutional holders of Atrium Therapeutics Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.

·CEO: Ms. Kathleen P. Gallagher

Frequently asked questions

What is Atrium Therapeutics Inc.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, Atrium Therapeutics Inc. has approximately 26.3 months of cash runway.

What is Atrium Therapeutics Inc.'s market capitalization?

Atrium Therapeutics Inc.'s market capitalization is approximately $218.1M.

Who is the CEO of Atrium Therapeutics Inc.?

Ms. Kathleen P. Gallagher is the chief executive officer of Atrium Therapeutics Inc. (RNA).

Get the full picture on Atrium Therapeutics Inc.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.